Introduction {#Sec1}
============

One of the major problems in the evaluation of data on clinical course and treatment efficacy in rare diseases is the absence of standardized databases derived from large numbers of patients assembled in an unbiased manner. Such data on natural course and benefits of early intervention are essential to support decisions on what to include in newborn screening (NBS) panels. To meet these needs for a specific group of inborn errors of metabolism, E-HOD, the European network and registry for homocystinurias and methylation defects (disturbed S-adenosylmethionine and S-adenosylhomocysteine ratio) was started in February 2013 (Table [1](#Tab1){ref-type="table"}, pathways depicted in Fig. [1](#Fig1){ref-type="fig"}). Aims of the project are, among others, the establishment of a disease registry for the collection of clinical, biochemical and genetic data, and the development of guidelines.Table 1Metabolic disorders addressed in this report, number of mutations, R4S data and population frequency/estimated number of patientsDisorder, gene and chromosomal locationMutationsNumber of patients with laboratory data in R4SEstimated number of patients/population frequencyORPHA codesMIM codesCystathionine-ß-synthase deficiency (classical homocystinuria); *CBS*; 21q22.3187^a^124\>1000\
1:344,000^c^394613381Severe *MTHFR* deficiency; 1p36.22101^b^17\>85395607093Cobalamin E (CblE) defect *MTRR*; 5p15.3126^a^\~502169602568Cobalamin G (CblG) defect *MTR*; 1q4322^a^\~502170156570Cobalamin C (CblC) defect *MMACHC*; 1p34.177^a^198\>30079282609831Cobalamin D (CblD) defect; *MMADHC*; 2q23.213^a^\<2079283\
308380\
308442611935Cobalamin F (CblF) defect; *LMBRD1*; 6q139^a^4\<2079284612625Cobalamin J (CblJ) defect; *ABCD4*; 14q24.35^a^0\<10369955603214Methionine adenosyltransferase (MAT I/III) deficiency;\
*MAT1A*; 10q23.148^a^1431:28,000^d^168598610550Glycine-N-mMethyltransferase (GNMT) deficiency;\
*GNMT*; 6p21.13^a^03289891606664S-adenosylhomocysteine hydrolase (SAHH) deficiency; *AHCY*; 20q11.2210^a^0888618613752Adenosine kinase (ADK) deficiency; *ADK*; 10q22.25 ^a^06289290102750All disorders are inherited as autosomal recessive traits with the exception of MATI/III deficiency, which may also beinherited as an autosomal dominant trait^a^Human Gene Mutation Database ([www.hgmd.org](http://www.hgmd.org/))^b^Burda P, personal communication^c^Skovby et al. ([@CR57])^d^Martins et al. ([@CR41]); Couce et al. ([@CR16])Fig. 1Homocystinurias and methylation disorders: metabolic pathways

The aims above are pursued in this report with respect to guidelines for NBS for the homocystinurias and methylation disorders developed on the basis of a systematic review of the literature, current NBS practice and expert discussions.

Methods {#Sec2}
=======

A systematic search of the Pubmed and Cochrane databases was performed using the search term "newbornscreening" in combination with every disease addressed by this report. To evaluate treatment efficacy, publications on clinical course, outcome and treatment were searched for.

After exclusion of publications containing no relevant information, study design and level of evidence was evaluated for 103 publications according to the "Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group (<http://www.gradeworkinggroup.org/>)" approach. Furthermore, data on metabolite concentrations in dried blood spots (DBS) at the time of screening obtained from 486 patients with subsequently confirmed homocystinurias and methylation disorders as well as cumulative data on distribution of analytes in healthy newborns and clinically validated target ranges for cut-off values were retrieved from the multi-center study "Region 4 Stork" (R4S) website (McHugh et al [@CR42]). In addition, EHOD partners were asked to contribute their non-published experience with NBS for the disorders of interest. The guidelines were established based on the literature evaluation and expert discussions following the GRADE approach. Expert consensus was targeted for each disease on the following key questions:Is the natural course of the disease severe?Is treatment generally beneficial?Is early intervention more effective?Are robust, valid and reliable methods, screening approaches and strategies available?

Results {#Sec3}
=======

Classical homocystinuria or cystathionine-ß-synthase deficiency {#Sec4}
---------------------------------------------------------------

### Clinical findings {#Sec5}

In classical homocystinuria or cystathionine-ß-synthase \[CBS\] deficiency, the condensation of serine and homocysteine (Hcy) to form cystathionine is disturbed as well as other processes such as the production of hydrogen sulphide from other substrates. Pyridoxal 5′-phosphate formed from dietary vitamin B~6~ is the essential cofactor of the enzyme. The true incidence of CBS deficiency is unknown; it has been estimated at 1:344.000 worldwide (Mudd et al [@CR46]) but due to different population frequencies and ascertainment methods, reports on CBS incidence vary largely. Molecular epidemiological studies predict frequencies between 1:6.400 and 1:20.500 in European populations (Gaustadnes et al [@CR25]; Refsum et al [@CR51]; Janosík et al [@CR32]).

Biochemical hallmarks of CBS deficiency are highly elevated concentrations of plasma total homocysteine (tHcy) combined with low plasma cystine or total cysteine, high normal to elevated plasma methionine (Met), low normal to decreased cystathionine, and a grossly abnormal cystathionine/Met ratio (Stabler et al [@CR58]; Bártl et al [@CR9]). Generally, patients present with ectopia lentis and myopia, mental retardation, marfanoid habitus and osteoporosis, thromboembolic events, developmental and behavioral problems (Mudd et al [@CR46]). If diagnosis is delayed, significant long-term morbidity must be expected (Naughten et al [@CR49]; Yap and Naughten [@CR70]). Milder forms and especially the pyridoxine-responsive variants of the disease due to specific mutations such as c.833 T \> C (p.I278T) may manifest later in adulthood e.g., with thromboembolic events or may even remain asymptomatic until adulthood (Skovby et al [@CR57]; Magner et al [@CR38]).

In the pyridoxine-responsive patients, variable doses of pyridoxine elicit near-normalization of biochemical parameters (Mudd et al [@CR46]). Patients with the more severe, pyridoxine non-responsive form of the disease are generally treated with a Met restricted diet mostly combined with supplementing amino acid mixtures enriched with cysteine. Many patients are treated with oral betaine, which provides methyl groups for homocysteine \[Hcy\] remethylation to Met (Adam et al [@CR3]). Treatment encompassed a combination of diet and betaine in 61 %, betaine alone in 34 % and diet alone in 5 % of 181 European pyridoxine non-responsive CBS patients (Adam et al [@CR3]).

Despite the variability of approaches, treatment effectively reduces morbidity, especially when initiated early. A significant reduction of vascular morbidity has been observed in 158 treated patients (Yap et al [@CR71]). While 112 vascular complications were predicted on the basis of historical data from untreated CBS deficient patients, only 17 vascular complications occurred in 12 patients (Yap et al [@CR71]). Thirteen CBS patients identified by NBS and with good compliance to treatment had normal full-scale IQ results (mean 105.8) in contrast to six poorly compliant (mean IQ 80.8) and two untreated patients (IQ 52 and 53) (Yap et al [@CR71]). These findings are supported by 11 patients diagnosed on NBS who developed no somatic symptoms and had a normal IQ (Walter et al [@CR65]). In 14 late diagnosed patients, all had lens subluxation/dislocation and impaired vision at diagnosis and eye disease progressed with less strict adherence to treatment. In contrast, 15 early treated patients had no evidence of lens subluxation and better visual acuity (Mulvihill et al [@CR48]).

#### Recommendation {#FPar1}

The severe form of CBS deficiency is defined by its significant morbidity (milder forms are also known). A large subgroup of patients is responsive to pyridoxine administration. Low methionine/low protein diet (mostly combined with methionine--free and cysteine enriched amino acid mixture) and/or betaine administration is effective in pyridoxine non-responsive CBS deficiency. Normal cognitive development and prevention of physical complications is possible in patients detected by NBS and treated early with continuous strict compliance.

### Methods for NBS in CBS deficiency {#Sec6}

Since the 1970s NBS for CBS deficiency has been based on the detection of increased Met concentration in dried blood spots (DBS) (Chace et al [@CR14]; Mudd [@CR45]). Long-term experience with the NBS for CBS deficiency exists namely in Ireland, Italy, Portugal, and some U.S. states (McHugh et al [@CR42]; Naughten et al [@CR49]; Peterschmitt et al [@CR50]; Accinni et al [@CR2]; Martins et al [@CR41]). Varying proportions (20--50 %) of missed pyridoxine non-responsive cases have been reported with different Met cut-off values used (Naughten et al [@CR49]; Gan-Schreier et al [@CR24]). Lowering of the Met cut-off from 138 to 67 μmol/L doubled the detection rate of CBS deficiency (Peterschmitt et al [@CR50]). Accordingly, Met cut-off values as low as 40 μmol/L have been proposed to yield higher sensitivity (McHugh et al [@CR42]; Turgeon et al [@CR63]). Sensitivity is also increased by using the Met/Phe ratio which adjusts for protein intake (Bowron et al [@CR11]). In conclusion, the primary factor driving sensitivity is the selection of as low as possible cut-off values for Met and Met/Phe ratio.

Although the pyridoxine responsive form of CBS deficiency is common in various populations and represented 44 % of patients in the historical cohort of 629 patients (Mudd et al [@CR46]), only 3--13 % of patients detected by NBS reported in the literature were pyridoxine responders (Mudd et al [@CR46]; Janosík et al [@CR32]). This marked discrepancy indicates that NBS programs using Met as the primary marker most likely fail to detect the majority of patients with pyridoxine responsive disease (Mudd [@CR45]).

Specificity of Met as the primary marker is poor since blood concentrations also increase in other disorders, e.g., liver disease, MATI/III, GNMT and SAHH deficiencies, and tyrosinemia type I (Mudd [@CR45]). Specificity may be improved by quantifying tHcy in DBS as a second-tier marker (Bártl et al [@CR9]; Turgeon et al [@CR63]; Alodaib et al [@CR5]) leading to a fivefold reduction of the false positive rate compared to the period when only Met at a cut-off of 40 μmol/L was used (Bowron et al [@CR11]).

Data on 124 CBS deficient patients ascertained by NBS show wide variation of the Met concentration in DBS with a clearly increased median of 103 μmol/L compared to the median of 20 μmol/L in healthy neonates (Table [3](#Tab3){ref-type="table"}) (McHugh et al [@CR42]). A target cut-off value for Met to differentiate the 99th centile in healthy newborns from the 5th centile in confirmed true positive cases recommended by R4S is in the range between 39 and 50 μmol/L. The Met/Phe ratio has slightly better performance characteristics. Data on tHcy in DBS as a secondary marker at the time of screening is available from 31 CBS deficient patients showing a clear distinction between cases (median tHcy 40 μmol/L) and controls (6 μmol/L). When tHcy is measured on the same specimen as a second tier test, calculating the Met/tHcy ratio may help differentiate the patients with CBS deficiency from MATI/III deficient individuals (see Table [3](#Tab3){ref-type="table"}).

The measurement of tHcy as primary NBS marker has only been used in the native Qatari population due to technical requirements and high costs (Gan-Schreier et al [@CR24]). Molecular genetic testing is feasible and may be an option for high-risk populations with a limited number of prevalent mutations. However, this approach will miss individuals carrying other mutations (Gan-Schreier et al [@CR24]).

#### Recommendation {#FPar2}

NBS for CBS deficiency can be performed by detecting elevated methionine, methionine-to-phenylalanine ratio and/or hyperhomocysteinemia in dried blood spots. However, total homocysteine has only exceptionally been used as a primary marker. Sensitivity of methionine as a primary marker for pyridoxine non-responsive CBS deficiency is limited and inversely related to the chosen cut-off concentrations of methionine. For the pyridoxine responsive form of the disease sensitivity is largely unknown and probably low. Specificity of methionine as a primary marker may be substantially increased by analyzing total homocysteine as a second tier marker and calculating the Met/tHcy ratio.

The combined remethylation defects cblC, cblF, cblJ, and cblD-MMA-Hcy {#Sec7}
---------------------------------------------------------------------

### Clinical findings {#Sec8}

The cblC defect, caused by mutations in the *MMACHC* gene is the most common of these defects (Lerner-Ellis et al [@CR37]). Mutations in the *LMBRD1* gene cause the cblF defect (Rutsch et al [@CR53]), and *ABCD4* mutations the cblJ defect (Coelho et al [@CR15]). Depending on type and location of the mutation in the *MMADHC* gene, the cblD defect either presents as isolated methylmalonic acid (MMA)-uria (cblD-MMA, beyond the scope of this report), combined MMA and homocystinuria (cblD-MMA-Hcy, resembling the cblC, cblF and cblJ defects) or isolated homocystinuria (cblD-Hcy, clinically indistinguishable from the cblE or cblG defect, addressed below) (Jusufi et al [@CR33]). All defects affect the synthesis of methylcobalamin, the co-factor for the cytosolic enzyme methionine synthase, and of adenosylcobalamin, the coenzyme for the intramitochondrial enzyme methylmalonyl-CoA mutase, which metabolizes MMA (Fig. [1](#Fig1){ref-type="fig"}). Thus low Met, elevated tHcy, propionylcarnitine and MMA are biochemical hallmarks of the disorders (McHugh et al [@CR42]; Fowler [@CR20]).

Main clinical symptoms of the early-onset form of the cblC defect (\<12 months, 88 % of cases) (Fischer et al [@CR19]) include failure to thrive, macrocytic anemia, muscular hypotonia, developmental delay, dysmorphic features, thinned corpus callosum, hydrocephalus, hemolytic uremic syndrome, and decreased visual acuity due to pigmentary retinopathy but no lens dislocation (Rosenblatt et al [@CR52]; Weisfeld-Adams et al [@CR68]; Fischer et al [@CR19]). Late-onset patients may present any time during childhood or adult life, typically with various combinations of myelopathy, dementia, psychiatric symptoms, hemolytic-uremic syndrome, thromboembolism, and pulmonary hypertension; retinopathy occurs rarely (Fischer et al [@CR19]; Huemer et al [@CR30]).

Treatment of the cblC defect --- which has also been applied in cblF, cblJ, and cblD-Hcy-MMA defects --- consists of intramuscular hydroxycobalamin (OH-Cbl), oral betaine and folate, rarely combined with Met supplementation. Carnitine is often added but has no proven effect (Martinelli et al [@CR40]). Dosages of medications vary considerably (Fischer et al [@CR19]; Carrillo-Carrasco et al [@CR13]).

In early-onset cblC patients, overall survival, hematological symptoms, and failure to thrive improve while eye disease and cognitive impairment often progress under treatment (Martinelli et al [@CR40]; Fischer et al [@CR19]). Despite identification by NBS and early treatment, 11/12 patients showed developmental delay, 8/9 brain pathologies, 10/11 muscular hypotonia, and 9/12 nystagmus at a mean age of 50 months (Weisfeld-Adams et al [@CR68]). However, from a screened and early treated cohort of 13 patients from Tuscany, the ten patients subjected to psychometric testing achieved a mean DQ of 80 or IQ of 85 compared to a mean DQ/IQ of 45 and 66 in 18 clinically diagnosed patients (mean age at diagnosis: 54 days). Only 7/13 screened and early treated patients developed the characteristic eye disease compared to 11/13 clinically diagnosed early-onset patients (Pasquini 2014, personal communication).

In most late-onset cblC patients, dementia, renal function, myelopathy, and axonal neuropathy improve on treatment. Long-lasting disease before treatment initiation correlates with incomplete recovery and residual pathologies (Huemer et al [@CR30]).

Clinical information is available for less than twenty patients with the cblF defect. Three patients died at 5, 9, and 10 months, respectively (Shih et al [@CR56]; Bowron et al [@CR11]; Alfadhel et al [@CR4]). In some early treated patients, neurocognitive outcome was good (Miousse et al [@CR44]; Armour et al [@CR6]), while in others severe developmental delay was present (Gailus et al [@CR23]; Alfadhel et al [@CR4]). For the cblJ defect (Coelho et al [@CR15]), clinical information on treatment outcome is extremely limited. Two patients reportedly responded well to treatment with methylcobalamin (Kim et al [@CR34]). In the reported cblD-Hcy-MMA cases, a broad spectrum of responses to treatment has been observed ranging from fatal progression of symptoms (Miousse et al [@CR43]) to improved (Suormala et al [@CR59]; Miousse et al [@CR43]) to even nearly normal development (Suormala et al [@CR59]) (Table [2](#Tab2){ref-type="table"}).Table 2Disease course and treatment response in homocystinurias and methylation disordersDiseaseDisease courseResponse to treatmentCBS deficiency B~6~-non responsiveSevereEarly, strict treatment results in favorable physical and cognitive outcome.CBS deficiency B~6~-responsiveMild to asymptomaticGood response to pyridoxinecblC defectSevereEarly-onset:\
Survival, hematological and microangiopathy symptoms responsive.\
Neurological, opthalmological and developmental problems often ongoing\
Late-onset:\
Predominantly responsive, residual myelopathy/neuropathy frequent in prolonged untreated coursescblD-Hcy defect\
cblD-MMA-Hcy defectSevereVariable, very limited datacblF defectSevereVariable, very limited datacblJ defectSevereVariable, very limited dataSevere MTHFR deficiencySevereEarly betaine treatment is beneficialcblE and cblG defectSevereTreatment seems beneficial in a majority of patients but response is variable. Individual case reports encourage early treatmentMAT I/III deficiency, heterozygous individualsPredominantly benignGenerally good without treatmentMAT I/III deficiency, compound heterozygote and homozygote individualsWhite matter disease, cognitive impairment observedMethionine-lowering treatment may be beneficial but data is very limitedGNMT deficiencyPredominantly benignGenerally good without treatmentSAHH deficiencySevereVariable, very limited dataADK deficiencySevereUnknown

#### Recommendation {#FPar3}

Screening for the cblC defect should be considered since in the early-onset CblC defect response to treatment has been observed for non-neurological symptoms with improved overall survival. The impact of early treatment on neurocognitive development and retinopathy is unclear. For late-onset patients treatment is mostly beneficial, especially when initiated before irreversible organ damage has occurred. The present knowledge allows no conclusion concerning the benefit of early treatment for the cblD-Hcy-MMA, cblF and cblJ defects.

### Methods for NBS in the combined remethylation defects {#Sec9}

Newborn screening for these defects has used the primary markers propionylcarnitine (C3), propionylcarnitine/acetylcarnitine (C3/C2) ratio, Met, and Met/Phe ratio. The R4S data indicate that the sensitivity of C3/C2 is superior to Met and Met/Phe. Indeed, the use of cut-off values for C3/C2 between 0.18 and 0.20 μmol/L differentiates between the 99th centile in healthy newborns and the 5th centile of cases with cblC, cblD-Hcy-MMA and cblF (McHugh et al [@CR42]). In contrast, both Met and Met/Phe will miss a considerable proportion of cases if used as a primary marker alone (McHugh et al [@CR42]) (Table [3](#Tab3){ref-type="table"}).Table 3Laboratory markers for newborn screening of homocystinurias and methylation defects in R4SDiseaseMarkerHealthy newborns-concentration in DBSPatients-concentration in DBSRecommended range for cut-off valueCommentNumber of laboratories with data1 %**median**99 %Number of patients1 %5 %**median**90 %99 %CBS deficiencyMet (μmol/L)15410.65**20**391242651**103**540964\>39--50possibly poor sensitivity for pyridoxine-responsive formMet/Phe920.23**0.41**0.751070.550.97**2.17**11.5025\>0.75--0.97tHcy (μmol/L)34.12**6.00**10.703112.4614.2**40**80158\>0.7--12.4Low Met/tHcy22.24**5.10**12.08290.860.93**2.24**4.295.75\<4.00--5.00cblC/cblDC3 acylcarnitine (μmol/L)1510.58**1.68**4.31982.653.46**8.40**13.319\>4.3--5.4poor sensitivityC3/C2 acylcarnitine1360.036**0.08**0.181870.130.20**0.39**0.621.67\>0.18--0.20MMA (μmol/L)30.010**0.20**1.52287.1310.94**28**114437\>3.0--7.0Methylcitrate (μmol/L)20.036**0.21**12.4100.370.38**0.63**6.1310.42\>0.7--1.2Met (μmol/L)15410.65**20**393.624.90**10.2**2647\<10.2--10.6poor sensitivityLow Met/Phe920.23**0.41**0.751780.0500.081**0.18**0.470.70\<0.17--0.23poor sensitivitytHcy (μmol/L)34.12**6.00**10.702314.6620**52.00**172241\>10.7--12.4cblFC3 acylcarnitine (μmol/L)1510.58**1.68**4.348.758.88**10.18**12.8713.76\>4.3--5.4cbE/cblG/ MTHFRLow Met (μmol/L)15410.65**20**39172.523.78**5.91**9.7610.22\<10.2--10.6Low Met/Phe920.23**0.41**0.75170.0380.068**0.10**0.160.17\<0.17--0.23tHcy (μmol/L)34.12**6.00**10.7084248**70**132154\>10.7--12.4Low Met/tHcy22.24**5.10**12.0880.0340.048**0.083**0.170.25\<4.00--5.00MATI/IIIMet (μmol/L)15410.65**20**391434450**103**173582\>39--50Met/Phe920.23**0.41**0.751370.841.1**1.77**3.726.32\>0.75--0.97Met/tHcy22.24**5.10**12.08210.8712.53**31**4852\>14.00--15.00

The specificity of C3 and/or C3/C2 for detecting these diseases is generally low (la Marca et al [@CR35]; Turgeon et al [@CR63]) since they also detect nutritional imbalances (including maternal vitamin B12 deficiency) or other inborn errors of metabolism (Scolamiero et al [@CR55]). Low Met has been proposed as a possible secondary marker (Weisfeld-Adams et al [@CR67]), but due to the above mentioned shortcomings, other second tier strategies have been developed, applying isolated or simultaneous measurement of MMA, methylcitric acid and tHcy (Alodaib et al [@CR5]; la Marca et al [@CR35]; Tortorelli et al [@CR62]; Fu et al [@CR22]). While methylcitric acid does not differentiate cblC/cblD patients from controls, the positive predictive value substantially increased from 4 to 100 % by measurement of MMA and from 11 to 36 % by measuring tHcy (la Marca et al [@CR35]; Turgeon et al [@CR63]).

#### Recommendation {#FPar4}

NBS for the cblC defect can be performed by identification of elevated propionylcarnitine with a high propionylcarnitine/acetylcarnitine ratio. Low methionine or low methionine/phenylalanine ratio are less sensitive. Sensitivity of propionylcarnitine and propionylcarnitine/acetylcarnitine ratio for detecting mild forms of the cblC defect is unknown. Specificity of biomarkers substantially increases by analyzing methylmalonic acid and/or total homocysteine in DBS as a second tier test. It can be anticipated that the same markers are useful for the detection of cblD-Hcy-MMA, cblF or cblJ disorders but efficacy and feasibility of screening for these three disorders is unknown. It should be noted that by using these markers, maternal vitamin B12 deficiency might be detected.

Isolated remethylation defects: the cblE, cblG, and cblD-Hcy defects, and severe MTHFR deficiency {#Sec10}
-------------------------------------------------------------------------------------------------

### Clinical findings {#Sec11}

The cblG defect affects the enzyme methionine synthase (MTR) while methionine synthase reductase (MTRR) is defective in the cblE defect (Watkins and Rosenblatt [@CR66]). The clinically similar cblD-Hcy defect was discussed above. All defects impair the remethylation of Hcy to Met and result in elevated tHcy and low normal to low Met (Stabler et al [@CR58]; Huemer et al [@CR31]).

The clinical pattern of the cblE and the cblG defect is indistinguishable. Mostly, initial symptoms evolve in the first year of life or in early childhood (Zavadakova et al [@CR72]). Macrocytic and/or megaloblastic anemia, failure to thrive and feeding difficulties, cognitive dysfunction, nystagmus, impaired visual acuity but no lens dislocation, and seizures are frequent. Microangiopathy and hemolytic uremic syndrome have only very rarely been described (Huemer et al [@CR31]). A subgroup of three patients from the Iberian Peninsula presented with isolated macrocytic anemia (Vilaseca et al [@CR64]).

Treatment encompasses folic or folinic acid, betaine and a variety of cobalamin (OH-Cbl, cyano- or methylcobalamin) preparations. Mostly tHcy and Met as well as macrocytic anemia (Fowler et al [@CR21]; Vilaseca et al [@CR64]) and neurocognitive performance (Fowler et al [@CR21]; Harding et al [@CR28]; Vilaseca et al [@CR64]; Müller et al [@CR47]; Schiff et al [@CR54]) respond well to treatment. In four patients, a positive impact of early treatment on outcome has been observed (Müller et al [@CR47]; Schiff et al [@CR54]). However, in a series of nine cblE patients, the overall impact of treatment on neurodevelopmental disabilities and eye disease was "at most moderate" (Zavadakova et al [@CR72]). Eye disease seems not to respond to treatment (Huemer et al [@CR31]).

Severe methylenetetrahydrofolate reductase (MTHFR) deficiency also results in defective methylation of Hcy to Met. The enzyme MTHFR catalyzes the reduction of 5,10 methylenetetrahydrofolate to 5-methyltetrahydrofolate, which serves as a methyl donor for the methylation of Hcy to Met (Fattal-Valevski et al [@CR18]). In addition to elevated tHcy and decreased Met the folate concentrations in plasma and especially in CSF are decreased in severe MTHFR deficiency (Thomas and Rosenblatt [@CR61]; Stabler et al [@CR58]). As in the combined defects, due to the enhanced flux through the transsulfuration pathway, plasma cystathionine (median 1192 nmol/L) is grossly elevated in patients compared to controls (median 157 nmol/L) (Stabler et al [@CR58]).

In severe MTHFR deficiency, developmental delay, seizures, and movement disorders are frequent in children. Adolescents and adults may present with psychiatric symptoms, neuropathy or thromboembolic events. Retinopathy has only rarely been reported (Thomas and Rosenblatt [@CR61]) but data from a mouse model show impaired retinal function (Lawrance et al [@CR36]). Megaloblastic and/or macrocytic anemia is usually absent (Thomas and Rosenblatt [@CR61]). Treatment with folate, folinic acid, Met, pyridoxine, and different cobalamin preparations has generally been considered unsuccessful (Thomas and Rosenblatt [@CR61]). However, Met supplementation improved the course in an early onset case (Abeling et al [@CR1]). In a systematic review including 36 patients, the positive impact of early betaine treatment on outcome in early-onset patients was shown (Diekman et al [@CR17]). Five early treated patients survived with normal psychomotor development while nine of ten non-treated and two late treated patients died. In families with one or more deceased siblings, none of the treated but all untreated children died. Psychomotor development was impaired in all children with delayed treatment onset, despite stabilization from introduction of treatment (Diekman et al [@CR17]) (Table [2](#Tab2){ref-type="table"}).

#### Recommendation {#FPar5}

NBS for severe MTHFR deficiency is recommended since early betaine administration is associated with a positive outcome. NBS for the cblD-Hcy, cblE, and cblG defects can be considered since in the majority of clinically diagnosed patients, treatment seems beneficial and there is some evidence for an added benefit of early treatment.

### Methods for NBS in the cblD-Hcy, cblE, and cblG defects, and severe MTHFR deficiency {#Sec12}

Neonatal screening for these disorders became possible only after the introduction of tandem mass spectrometry for determination of decreased Met concentration in DBS (Chace et al [@CR14]). Data on 18 remethylation cases were available in R4S (four MTHFR, one cblG, and one cblE and 12 non-classified cases). The Met concentration in the DBS was decreased to a median of 5.91 μmol/L in the patients, with no overlap with healthy newborns (Table [3](#Tab3){ref-type="table"}). In addition, both the Met/Phe ratio (Bowron et al [@CR11]) and the second-tier marker tHcy clearly differentiate patients from controls (Tortorelli et al [@CR62]; McHugh et al [@CR42]).

In theory, tHcy can be employed as the primary screening marker but there are no published data on its use. There are no long-term data on efficacy of screening programs for these disorders (Tortorelli et al [@CR62]) owing to their rarity and low proportion of screening programs addressing decreased Met or Met/Phe ratio (in R4S, 162 laboratories have listed a high cut-off for methionine, but only 73 have a low cut-off value).

#### Recommendation {#FPar6}

Neonatal screening for the cblD-Hcy, cblE, and cblG defects, and for MTHFR deficiency appears to be possible by detecting a decreased methionine and methionine-to-phenylalanine ratio in DBS followed by analysis of total homocysteine as a second tier marker. Efficacy and feasibility of screening for these disorders is largely unknown.

Methionine adenosyltransferase deficiency {#Sec13}
-----------------------------------------

### Clinical findings {#Sec14}

Methionine adenosyltransferase (MAT) catalyses the formation of S-adenosylmethionine (AdoMet) from Met. Three variant forms (MAT I, II and III) of the enzyme have been described. The MAT I and III --- encoded by a single gene (*MAT1A*) --- are expressed mainly in liver. The MATII is expressed ubiquitously in extrahepatic tissues and seems to play a pivotal role in maintaining whole body AdoMet homeostasis. Homozygosity or compound heterozygosity for *MAT1A* mutations and heterozygosity for some mutations result in hypermethioninemia without elevation of AdoMet concentrations. Inheritance of this biochemical trait may thus be autosomal recessive or autosomal dominant (Baric [@CR7]).

There is evidence that a small number of individuals homozygous or compound heterozygous for *MAT1A* mutations develop myelination defects or white matter disease and some of these patients are cognitively impaired. These clinical signs have been related to persistent very high Met concentrations and/or to AdoMet deficiency in the brain (17, 63). It is advisable to monitor these patients closely and to consider introduction of a Met restricted diet or AdoMet supplementation. The available evidence suggests that AdoMet supplementation may normalize existing white matter changes (Surtees et al. [@CR60]).

However, the most common autosomal dominant form of hypermethioninemia detected by neonatal screening is caused by heterozygosity for the mutation c. 791G \> A (p.R264H). Since the clinical course in these individuals is generally benign (Baric [@CR7]; Mudd [@CR45]), the impact of a protein-controlled diet cannot clearly be evaluated (Couce et al [@CR16]) and the usefulness of early detection of these individuals is questionable (Mudd [@CR45]; Blom 2014, personal communication) (Table [2](#Tab2){ref-type="table"}).

#### Recommendation {#FPar7}

In individuals heterozygous for MAT I/III deficiency, treatment seems not to be necessary. Patients homozygous/compound heterozygous for MAT I/III mutations should be monitored closely and may require intervention. Data on the benefit of early intervention is lacking.

### Methods for NBS in MATI/III {#Sec15}

Most MAT I/III deficient individuals were originally identified by NBS programs targeting CBS deficiency (Mudd [@CR45]) and the number of detected individuals substantially increased with use of lower Met cut-off values between 45 and 54 μmol/L (Martins et al [@CR41]). The incidence is especially high in the Galicia region of Spain and in Portugal (1:26.000-1: 28.163), mostly due to heterozygosity for the p.R264H mutation (Martins et al [@CR41]; Couce et al [@CR16]). The DBS concentrations of Met in 143 MAT I/III deficient individuals (including carriers) in the R4S database reached a median of 103 μmol/L compared to the median of 20 μmol/L in healthy neonates (McHugh et al [@CR42]). A target cut-off value for Met to differentiate between the 99th centile in healthy newborns from the 5th centile in confirmed true positive cases is consequently in the range between 39 and 50 μmol/L (Table [3](#Tab3){ref-type="table"}). The Met/Phe ratio has similar performance characteristics (McHugh et al [@CR42]). Differentiation between MATI/III and CBS deficiency based on Met concentrations is not possible. However, determination of tHcy concentration as second tier strategy and then calculating the Met/tHcy ratio may discriminate between CBS and MATI/III deficiency; a simple and effective approach is to apply the dual scatter plot functionality available on the website of the R4S collaborative project (Table [3](#Tab3){ref-type="table"}).

#### Recommendation {#FPar8}

Individuals with MATI/III deficiency have been predominantly detected in NBS programs for CBS deficiency due to increased methionine concentrations. The majority of these newborns are heterozygotes for the mutation c.791G \> A and the benefit of detecting these individuals is questionable. At present, there is no primary marker to differentiate between MATI/III and CBS deficiency. Data on the Met/tHcy ratio to differentiate between these two conditions are promising but limited.

Glycine-N-methyltransferase deficiency, S-adenosylhomocysteine hydrolase deficiency and adenosine kinase deficiency {#Sec16}
-------------------------------------------------------------------------------------------------------------------

Another disorder characterized by isolated hypermethioninemia is glycine-N-methyltransferase (GNMT) deficiency, which has only been described in three individuals. GNMT transfers a methyl group from S-adenosylmethionine to glycine and thus synthesizes sarcosine. Deficiency of the enzyme results in gross elevation of AdoMet and Met concentrations. GNMT deficiency seems to be a relatively benign disorder presenting with mild hepatomegaly or moderately elevated liver transaminases (Baric [@CR7]). At present, the rarity and the benign course of the condition do not support inclusion in NBS programmes (Mudd [@CR45]).

The enzyme S-adenosylhomocysteine hydrolase (SAHH) catalyses the hydrolysis of S-adenosylhomocysteine to Hcy and adenosine. SAHH deficiency has been described in seven patients (Honzík et al [@CR29]). Biochemical findings include grossly increased S-adenosylhomocysteine with elevation of S-adenosylmethionine and Met while tHcy may be normal or mildly elevated. The clinical course in the first male index patient from Croatia revealed a severe disease with myelination disorder and low IQ, hepatopathy and myopathy with elevated creatine kinase. The pathogenesis of myopathy in SAHH deficiency is at present not completely understood. While Met restriction had a positive impact on neurocognitive symptoms even in the index patient and improved the course significantly in the patient's two early diagnosed and treated brothers, myopathy persisted in all cases (Barić et al [@CR8]; Baric [@CR7]). In another patient, treatment from the age of 5 months to 5 years failed to prevent clinical symptoms (Baric [@CR7]; Mudd [@CR45]). Recently two siblings with hydrops fetalis and fatal outcome have been reported (Grubbs et al [@CR26]), underlining the severity of the disease.

The enzyme ADK catalyzes the phosphorylation of adenosine, which is produced by hydrolysis of S-adenosylhomocysteine by SAHH. When adenosine is not further metabolized, its accumulation inhibits S-adenosylhomocysteine hydrolase leading also to an increase of the upstream metabolites S-adenosylmethionine and methionine (Bjursell et al [@CR10]). Until now adenosine kinase (ADK) deficiency has been described in six patients: two Swedish siblings and two related pairs of Malaysian siblings with severe developmental delay, macrocephaly, epilepsy, and abnormal liver function. One patient died at the age of 10 years. All patients shared the biochemical pattern of elevated methionine, S-adenosylmethionine, and S-adenosylhomocysteine levels in the presence of normal/slightly elevated tHcy similar to SAHH deficiency. The detection of increased urinary adenosine may be useful to differentiate this defect from SAHH deficiency, in which elevated creatine kinase activity can also be expected. Methionine restriction may be beneficial in some patients (Mudd [@CR45]). Patients may be identified by NBS programs based on elevated Met (Buist et al [@CR12]), however no targeted NBS approaches for SAHH and ADK deficiencies have been reported so far.

### Recommendation {#FPar9}

GNMT appears to be a benign condition. In the very small numbers of patients described, SAHH and ADK deficiency are predominantly severe disorders. Present knowledge allows no conclusive statement concerning the benefit of early treatment for SAHH and ADK deficiency. Neonatal screening for SAHH and ADK deficiency cannot be recommended at this stage due to lack of data and validated screening strategies.

Conclusion {#Sec17}
==========

Selection of diseases for NBS must be driven by clinical arguments --- a severe disease, generally not detectable early in life on a clinical basis, feasible and effective treatment, and a better outcome in early treated individuals meets accepted criteria for inclusion into a NBS program (Wilson and Jungner [@CR69]). However, the evidence for efficacy of treatment in the homocystinurias and methylation disorders is limited due to small series of subjects with different genotypes, varying treatment, and inconsistent follow-up strategies. Particularly, time of initiation of treatment and the use, dosage, and intervals of application of drugs are far from uniform.

However, despite the above-mentioned limitations of clinical data, there is robust evidence for successful treatment and improved outcome by early treatment for CBS deficiency, and to a lesser extent for MTHFR deficiency and the cblC defect. In CBS deficiency, good outcome in individuals identified by NBS is consistently reported even from various centers including patients with a variety of *CBS* mutations and despite a large variability in treatment practice (Naughten et al [@CR49]; Walter et al [@CR65]). In MTHFR deficiency, the clear clinical effect of early treatment with betaine is an important supporting evidence for screening (Diekman et al [@CR17]). In the late-onset cblC defect, treatment response is seen in almost all patients but residual disease manifestations are frequent in patients with long duration of clinical abnormalities before treatment initiation (Huemer et al [@CR30]). Evidence for efficacy of early treatment is less clear for the early-onset cblC defect in which survival, hematological symptoms, and feeding problems often improve, while the effect on neurocognitive development and retinopathy is less encouraging (Weisfeld-Adams et al [@CR68]).

If screening for these disorders is advisable from a clinical point of view, robust, applicable, and widely accepted primary and secondary markers must be used. The respective markers and ratios should be developed and their utility tested by combining a large amount of data and by application of post-analytical interpretative tools (Marquardt et al [@CR39]; Hall et al [@CR27]). Algorithms and cut-offs for markers based on small isolated case series have a significant risk of bias and may be misleading. However, even with the use of large sample numbers the selection of reliable cut-off values for NBS based on comparing data from patients detected by the NBS methods and values from healthy newborns is not trivial. Very little data is available on missed cases and milder forms of the screened diseases, which may manifest years or even decades later. Therefore, it must be kept in mind that NBS markers reflect the present state of the art, which is temporary and may change in the future due to technological advances and improved knowledge.

For the other disorders addressed by this review, there is either only weak evidence for a response to treatment and for the specific value of early treatment \[cblE and cblG defects\] (Vilaseca et al [@CR64]; Zavadakova et al [@CR72]), or insufficient data to evaluate treatment outcome \[cblD, cblF, cblJ, GNMT, SAHH, and ADK deficiency\]. It must be emphasized that NBS programs targeting CBS, MTHFR or cblC will most probably identify also subjects with other homocystinurias/methylation disorders with uncertain clinical relevance and that biochemical algorithms to differentiate between all these disorders must be established. On one hand, this will allow a more differentiated view regarding the benefit of early detection and treatment for these disorders and facilitate genetic counselling for families with severely affected children. On the other hand, subjects requiring no treatment and follow-up may also be detected. A paradigm for this process is the MAT I/III defect for which data on clinical severity are conflicting. Heterozygosity for specific *MAT1A* mutations is considered benign and these individuals should not but will be picked up. However, a small but significant number of individuals homozygous or compound heterozygous for *MAT1A* mutations may develop clinical complications and may benefit from treatment.

To improve the overall knowledge on homocystinurias and methylation disorders, studies on the natural course, treatment, and outcome following a structured scheme are needed. The E-HOD registry is collecting data on a large number of patients to create a large, standardized database and thereby facilitate and support considerations on whether to recommend inclusion or exclusion of these disorders into/from NBS panels.

ADK

:   adenosine kinase

C2

:   carnitine, acetylcarnitine

C3

:   carnitine propionylcarnitine

CBS

:   cystathionine beta-synthase

DBS

:   dried blood spots

GNMT

:   glycine-N-methyltransferase

Hcy

:   homocysteine

MAT

:   methionine adenosyltransferase

MMA

:   methylmalonic acid

Met

:   methionine

MTHFR

:   methylenetetrahydrofolate reductase

NBS

:   newborn screening

OH-Cbl

:   hydroxycobalamin

R4S

:   Region 4 Stork

SAHH

:   S-adenosylhomocysteine hydrolase

tHcy

:   total homocysteine
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